Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib with Chemotherapy and Blinatumomab in Pediatric and Young Adult r/r Ph+ or Ph-like ALL
NCT07387926Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Primary completion
- Sep 2033
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of asciminib in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Adverse Events at 4 weeks and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
asciminib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07387926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387926.